Get the Stockscreener App
0.144
41.04%
0.0419
After Hours:
.14
-0.004
-2.78%
Geovax Labs Inc stock is traded at $0.144, with a volume of 24,413.
It is up +41.04% in the last 24 hours and up +20.00% over the past month.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
See More
Previous Close:
$0.1021
Open:
$0.1025
24h Volume:
24,413
Relative Volume:
0.73
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+30.91%
1M Performance:
+20.00%
6M Performance:
+144.07%
1Y Performance:
+0.00%
1-Day Range:
$0.102
$0.195
1-Week Range:
$0.095
$0.228
52-Week Range:
$0.02
$34.93
Geovax Labs Inc Stock (GOVXW) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678 384 7220
Address
1900 Lake Park Drive, Suite 380, Smyrna
Compare GOVXW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| GOVXW | 0.144 | 0 | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Geovax Labs Inc Stock (GOVXW) Latest News
Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World
Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia
Brokerages Set GeoVax Labs, Inc. (NASDAQ:GOVX) PT at $12.67 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2024 Earnings Call Transcript - MSN
Earnings call: GeoVax reports progress in vaccine trials, financial updates - Investing.com
U.S. Stock market top losers: Gaucho Group Holdings sees decline of 55.06% while GeoVax Labs looses 23.53% in early trading - Business Upturn
Alliance Global Partners Initiates Coverage on GeoVax Labs (NASDAQ:GOVX) - Defense World
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - Yahoo Finance
GeoVax Labs Reports Improved Earnings and Strategic Progress - TipRanks
GeoVax Labs reports Q3 EPS (91c), consensus ($1.48) - TipRanks
GeoVax Reports Progress on COVID-19 Vaccine and Cancer Therapies in Q3 2024 Financial Results - Citybuzz
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
GeoVax Q3 Loss Narrows to $5.8M as BARDA Contract Boosts Revenue to $2.8M | GOVX Stock News - StockTitan
GeoVax Labs initiated with a Buy at Alliance Global Partners - Yahoo Finance
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday - Benzinga
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 - GlobeNewswire
Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross? - MSN
GeoVax expands offering size to $30 million By Investing.com - Investing.com Australia
GeoVax expands offering size to $30 million - Investing.com India
Geovax Labs (STU:E8LA) Intrinsic Value: Projected FCF : €-111.10 (As of Oct. 16, 2024) - GuruFocus.com
GeoVax postpones stockholder meeting due to low turnout - Investing.com
GeoVax postpones stockholder meeting due to low turnout By Investing.com - Investing.com UK
GeoVax stock rockets 50% on BARDA award for COVID-19 vaccine - MSN
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying - MSN
Market Insight: Geovax Labs Inc (GOVX)’s Notable Drop, Closing at 2.03 - The Dwinnex
Geovax Labs Inc (GOVX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Buying Buzz: Geovax Labs Inc [GOVX] President, CEO DODD DAVID A purchases 8,000 shares of the company - Knox Daily
GOVX’s 52-Week Rollercoaster: From $1.09 to $11.18 – What’s Next for Investors? - The InvestChronicle
Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
Views of Wall Street’s Leading Experts on Geovax Labs Inc - SETE News
Investing in Geovax Labs Inc (GOVX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Keeping an Eye on Geovax Labs Inc (GOVX) After Insider Trading Activity - Knox Daily
GeoVax Labs reports quorum shortfall, delays Special Meeting By Investing.com - Investing.com Australia
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
Closing Figures: Geovax Labs Inc (GOVX)’s Negative Finish at 2.20, Down -8.71 - The Dwinnex
GeoVax Labs reports quorum shortfall, delays Special Meeting - Investing.com India
Geovax Labs Inc [NASDAQ: GOVX] Sees Decrease in Stock Value - Knox Daily
GeoVax Labs inks sales agreement, may offer stock By Investing.com - Investing.com Canada
GeoVax Labs inks sales agreement, may offer stock - Investing.com India
Form 424B5 GeoVax Labs, Inc. - StreetInsider.com
GeoVax Labs, Inc. (NASDAQ:GOVXW) Short Interest Update - Defense World
Nothing is Better Than Geovax Labs Inc (GOVX) stock at the moment - SETE News
Monitoring Geovax Labs Inc (GOVX) after recent insider movements - Knox Daily
Globus Medical, Inc. (NYSE:GMED) Shares Purchased by Envestnet Asset Management Inc. - MarketBeat
GEELY AUTO Partners with Tasco to Set Up Auto Assembly Plant in Vietnam w/ Total Investment Amt ~US$168M - AASTOCKS.com
GameStop up after raising $400 mln from equity offering - XM
Gevo Inc (GEVO) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Gevo Inc (GEVO) stock: A year of ups and downs - US Post News
GOVX’s Stock Market Adventure: -45.52% YTD Growth Amidst Volatility - The InvestChronicle
Trading Day Review: Geovax Labs Inc (GOVX) Gains Momentum, Closing at 2.95 - The Dwinnex
Geovax Labs Inc Stock (GOVXW) Financials Data
There is no financial data for Geovax Labs Inc (GOVXW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Cap:
|
Volume (24h):